サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1799073

切除不能肝細胞がんの世界市場

Unresectable Hepatocellular Carcinoma

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
切除不能肝細胞がんの世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

切除不能肝細胞がんの世界市場は2030年までに23億米ドルに達する見込み

2024年に21億米ドルと推定される切除不能肝細胞がんの世界市場は、2024～2030年の分析期間においてCAGR 2.2%で成長し、2030年には23億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである切除不能肝細胞がんの化学療法は、CAGR 2.9％を記録し、分析期間終了までに13億米ドルに達すると予測されます。分子標的治療分野の成長率は、分析期間中CAGR 1.1％と推定されます。

米国市場は5億6,030万米ドルと推定、中国はCAGR4.4％で成長予測

米国の切除不能肝細胞がん市場は、2024年に5億6,030万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億4,720万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.7%と1.6%と予測されています。欧州では、ドイツがCAGR 1.2%で成長すると予測されています。

世界の切除不能肝細胞がん市場- 主要動向と促進要因のまとめ

手術不能な肝細胞がん患者の治療経路はどのように進化しているか？

切除不能肝細胞がん（uHCC）は原発性肝がんのかなりの部分を占め、外科的切除が困難な腫瘍や、罹患患者の肝予備能の低下により、臨床的に大きな課題を提示しています。経動脈的化学塞栓療法（TACE）や経動脈的放射性塞栓療法（TARE）のような従来の局所療法への依存は、全身治療における最近のブレークスルーに牽引され、より統合的な治療アプローチへと徐々にシフトしています。進化する治療パラダイムは現在、免疫腫瘍学、抗血管新生剤、および併用レジメンによって定義され、病期や肝機能に合わせて治療を個別化するための選択肢を臨床医に提供しています。

チェックポイント阻害剤、特にニボルマブやアテゾリズマブなどのPD-1およびPD-L1モノクローナル抗体は、uHCCの一次治療および二次治療として承認されています。IMbrave150試験では、アテゾリズマブとベバシズマブの併用が、それまで標準治療であったソラフェニブよりも全生存期間と無増悪生存期間において有意に優れていることが示されました。この開発により、治療方針は免疫抑制と腫瘍血管新生のデュアルターゲットへとシフトしました。さらに、トレメリムマブとデュルバルマブを含む試験（STRIDEレジメン）から得られた新たなデータは、免疫療法の併用が生存予後をさらに改善する可能性を示しています。このような臨床的シフトは、全身療法の役割を再定義し、uHCC管理における治療効果の新たな基準を設定しつつあります。

薬剤開発と精密治療における新たな方向性とは？

切除不能肝細胞がんのパイプラインは急速に拡大しており、臨床開発の様々な段階にある低分子化合物、モノクローナル抗体、T細胞モジュレーターの数が増加しています。ソラフェニブやレンバチニブのような初期の治療薬がマルチキナーゼ阻害の基礎を築いた一方で、カボザンチニブやレゴラフェニブのような次世代チロシンキナーゼ阻害剤（TKI）は、様々なシーケンス戦略や併用レジメンで研究されています。これらの薬剤はより幅広い標的プロファイルを示し、腫瘍の増殖、脈管形成、転移に重要な経路を阻害することが可能です。さらに、AFP（α-フェトプロテイン）やc-MET過剰発現などのバイオマーカーの統合は、バイオマーカーに誘導された治療方針決定へのシフトを促しています。

プレシジョン・メディシンは薬剤開発の中心的なテーマとして浮上しており、特にゲノム・プロファイリング技術が肝がん治療に採用されつつあります。腫瘍の変異負荷、PD-L1発現、特定の遺伝子融合は、現在、臨床試験の適格基準として検討されています。さらに、循環腫瘍DNA（ctDNA）を用いたリキッドバイオプシー・プラットフォームは、リアルタイムの疾患モニタリングや治療反応性評価のための非侵襲的ツールとして普及しつつあります。uHCCの分子的不均一性や肝硬変、B/C型肝炎感染、NASHを原因とする肝疾患との相互作用を研究者が解明するにつれて、標的薬剤開発は、一元的な治療戦略から、ニュアンスのある患者特異的なアプローチへとますます軸足を移していくと思われます。

マルチモーダルおよびインターベンショナルアプローチはどこで台頭しているのか？

全身療法の台頭にもかかわらず、全身的治療と局所的治療を組み合わせた多剤併用療法が中・進行期のuHCCに採用されることが多くなっています。臨床では、TACE後に全身免疫療法を行う、あるいは定位放射線治療（SBRT）とチェックポイント阻害薬を併用するなどの橋渡し療法が、無増悪期間の延長と腫瘍制御率の改善において有望視されています。場合によっては、これらの戦略によりダウンステージが成功し、以前は手術不能であった患者が切除や移植などの根治的治療の対象となります。

インターベンショナル・ラジオロジーの役割は、マイクロ波焼灼術や薬剤溶出性ビーズ塞栓術などの画像誘導療法によって拡大し続けており、これらは現在、全身免疫療法と併用されています。さらに、AIを活用した画像解析と機能的MRI評価は、より良い患者選択と治療効果の早期予測をサポートしています。腫瘍の容積反応と脈管侵襲に基づいて治療計画を動的に適応させる能力は、切除不能な疾患を管理するためのより洗練された積極的なアプローチを可能にしています。医療機関も腫瘍委員会主導の決定に向かっており、腫瘍内科医、肝臓内科医、放射線科医、外科医の学際的な連携により、治療経路の標準化が進み、集学的臨床試験への登録が加速しています。

世界のuHCC治療市場拡大の原動力は？

切除不能肝細胞がん市場の成長は、世界の肝がん罹患率の上昇、免疫療法へのアクセス拡大、先進生物学的製剤や併用レジメンに対する償還の改善など、いくつかの要因によってもたらされます。肝細胞がんは、世界的に原発性肝がんの75％以上を占めており、慢性B型肝炎の流行により東アジアとサハラ以南のアフリカで、またアルコール性肝疾患とNASHにより欧米で、それぞれ負担が増加しています。多くの地域で早期発見が依然として少ないため、患者の大半は切除不能な段階で診断され、全身療法や多剤併用療法に対応できる患者層が拡大しています。

市場の成長は、FDAの画期的治療薬指定、EMAの条件付き承認、中国の国家医薬品監督管理局（NMPA）による免疫腫瘍薬の優先的迅速審査など、規制の加速化によってさらに可能となります。アテゾリズマブ＋ベバシズマブのような治療薬が、主要な臨床ガイドラインや各国の処方箋に含まれることで、医師による取り込みが拡大し、標準治療が世界的に整いつつあります。さらに、次世代シークエンシングやコンパニオン診断薬へのアクセスが改善したことで、個別化医療へのシフトが強化され、患者サブセット全体で免疫療法の有用性が拡大しています。製薬企業と学術がんセンターとの戦略的パートナーシップも、コンビナトリアル試験やバイオマーカーに関連した治療法の開発を促進しています。これらの力学が相まって、アンメット・クリニカル・ニーズが大きく、商業的投資が拡大している、革新主導型の強固な世界市場が形成されつつあります。

セグメント

治療（切除不能肝細胞がんの化学療法、分子標的療法、免疫療法、その他の治療）、エンドユーザー（病院エンドユーザー、がんセンターエンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene Ltd.（BeOne Medicines）
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb
  • Can-Fite Biopharma
  • CStone Pharmaceuticals
  • Delcath Systems Inc.
  • Eisai Co. Ltd.
  • Elevar Therapeutics
  • Exelixis Inc.
  • F. Hoffmann-La Roche Ltd.
  • Halozyme Therapeutics Inc.
  • Innovent Biologics Inc.
  • Jiangsu HengRui Medicine Co. Ltd.
  • Johnson & Johnson
  • Medivir AB
  • Merck & Co., Inc.
  • Moderna, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP39469

Global Unresectable Hepatocellular Carcinoma Market to Reach US$2.3 Billion by 2030

The global market for Unresectable Hepatocellular Carcinoma estimated at US$2.1 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Chemotherapy for Unresectable Hepatocellular Carcinoma, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Molecularly Targeted Therapy segment is estimated at 1.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$560.3 Million While China is Forecast to Grow at 4.4% CAGR

The Unresectable Hepatocellular Carcinoma market in the U.S. is estimated at US$560.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$447.2 Million by the year 2030 trailing a CAGR of 4.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Unresectable Hepatocellular Carcinoma Market - Key Trends & Drivers Summarized

How Are Therapeutic Pathways Evolving for Patients with Inoperable Hepatocellular Carcinoma?

Unresectable hepatocellular carcinoma (uHCC), representing a significant portion of primary liver cancer cases, presents substantial clinical challenges due to the inaccessibility of tumors to surgical resection and the compromised hepatic reserve in affected patients. The traditional reliance on locoregional therapies such as transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) has gradually shifted to a more integrated therapeutic approach, driven by recent breakthroughs in systemic treatments. The evolving therapeutic paradigm is now defined by immuno-oncology, anti-angiogenic agents, and combination regimens, offering clinicians more options to personalize treatment in alignment with disease stage and liver function.

Checkpoint inhibitors, notably PD-1 and PD-L1 monoclonal antibodies such as nivolumab and atezolizumab, have received regulatory approval for first- and second-line treatment in uHCC. The IMbrave150 trial demonstrated significant overall survival and progression-free survival benefits of atezolizumab combined with bevacizumab over sorafenib, which had previously been the standard of care. This development shifted the treatment landscape toward dual targeting of immune suppression and tumor angiogenesis. Moreover, emerging data from trials involving tremelimumab and durvalumab (STRIDE regimen) indicate that combination immunotherapies may further enhance survival outcomes. These clinical shifts are redefining the role of systemic therapies and setting new benchmarks for treatment efficacy in uHCC management.

What Are the New Directions in Drug Development and Precision Therapy?

The pipeline for unresectable hepatocellular carcinoma is expanding rapidly, marked by an increasing number of small molecules, monoclonal antibodies, and T-cell modulators in various phases of clinical development. While early therapies like sorafenib and lenvatinib provided a foundation in multikinase inhibition, next-generation tyrosine kinase inhibitors (TKIs) such as cabozantinib and regorafenib are being studied in various sequencing strategies and combination regimens. These agents exhibit broader target profiles, allowing inhibition of pathways critical for tumor proliferation, vascularization, and metastasis. Additionally, the integration of biomarkers such as AFP (alpha-fetoprotein) and c-MET overexpression is driving a shift toward biomarker-guided therapeutic decision-making.

Precision medicine is emerging as a central theme in drug development, particularly as genomic profiling technologies are being adopted in liver cancer care. Tumor mutational burden, PD-L1 expression, and specific gene fusions are now being explored as eligibility criteria in clinical trials. Moreover, liquid biopsy platforms using circulating tumor DNA (ctDNA) are gaining traction as non-invasive tools for real-time disease monitoring and therapeutic response evaluation. As researchers decode the molecular heterogeneity of uHCC and its interplay with cirrhosis, hepatitis B/C infection, and NASH-driven liver disease, targeted drug development will increasingly pivot from monolithic treatment strategies to nuanced, patient-specific approaches.

Where Are Multimodal and Interventional Approaches Gaining Ground?

Despite the rise of systemic therapies, multimodal treatment strategies that combine systemic and locoregional interventions are increasingly adopted for intermediate and advanced-stage uHCC. In clinical practice, bridging therapies such as TACE followed by systemic immunotherapy or stereotactic body radiation therapy (SBRT) combined with checkpoint inhibitors are showing promise in expanding progression-free intervals and improving tumor control rates. In some cases, these strategies are leading to successful downstaging, making previously inoperable patients eligible for curative interventions such as resection or transplantation.

The role of interventional radiology continues to expand with image-guided therapies such as microwave ablation and drug-eluting bead embolization, which are now being used in tandem with systemic immunotherapies. Moreover, AI-enabled imaging analytics and functional MRI assessments are supporting better patient selection and earlier prediction of treatment response. The ability to dynamically adapt treatment plans based on volumetric tumor response and vascular involvement is enabling a more refined and proactive approach to managing unresectable disease. Medical institutions are also moving toward tumor board-driven decisions, where multi-disciplinary collaboration between oncologists, hepatologists, radiologists, and surgeons is standardizing care pathways and accelerating enrollment into multimodal clinical trials.

What Is Driving the Expansion of the Global uHCC Treatment Market?

The growth in the unresectable hepatocellular carcinoma market is driven by several factors, including rising global incidence of liver cancer, expanded access to immunotherapy, and improved reimbursement for advanced biologics and combination regimens. Hepatocellular carcinoma accounts for over 75% of primary liver cancer cases globally, with a disproportionate burden observed in East Asia and Sub-Saharan Africa due to chronic hepatitis B prevalence, and increasingly in the West due to alcoholic liver disease and NASH. As early-stage detection remains low in many regions, the majority of patients are diagnosed at unresectable stages, expanding the addressable patient pool for systemic and multimodal treatments.

Market growth is further enabled by regulatory acceleration, including FDA breakthrough therapy designations, EMA conditional approvals, and China’s National Medical Products Administration (NMPA) prioritizing fast-track reviews for immuno-oncology agents. The inclusion of therapies such as atezolizumab + bevacizumab in major clinical guidelines and national formularies is broadening physician uptake and standard-of-care alignment globally. Additionally, improved access to next-generation sequencing and companion diagnostics is reinforcing the shift to personalized medicine and expanding the utility of immunotherapies across patient subsets. Strategic partnerships between pharma companies and academic cancer centers are also catalyzing the development of combinatorial trials and biomarker-linked therapies. Collectively, these dynamics are shaping a robust, innovation-driven global market with significant unmet clinical need and growing commercial investment.

SCOPE OF STUDY:

The report analyzes the Unresectable Hepatocellular Carcinoma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy, Other Treatments); End-User (Hospitals End-User, Cancer Centers End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene Ltd. (BeOne Medicines)
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb
  • Can-Fite Biopharma
  • CStone Pharmaceuticals
  • Delcath Systems Inc.
  • Eisai Co. Ltd.
  • Elevar Therapeutics
  • Exelixis Inc.
  • F. Hoffmann-La Roche Ltd.
  • Halozyme Therapeutics Inc.
  • Innovent Biologics Inc.
  • Jiangsu HengRui Medicine Co. Ltd.
  • Johnson & Johnson
  • Medivir AB
  • Merck & Co., Inc.
  • Moderna, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Unresectable Hepatocellular Carcinoma - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Liver Cancer Throws the Spotlight on Treatment Demand for Unresectable HCC
    • Advancements in Immuno-Oncology Spur Growth in Immune Checkpoint Inhibitor Therapies for uHCC
    • Expansion of Targeted Therapy Approvals Expands Addressable Market for Precision Medicine in Advanced Liver Cancer
    • Limitations of Surgical and Curative Options Strengthen the Business Case for Systemic and Locoregional Therapies
    • Increased Use of Combination Regimens Drives Adoption of Multi-Mechanism Treatment Approaches
    • Biomarker-Driven Patient Stratification Accelerates Demand for Personalized Treatment Pathways
    • Growing Clinical Evidence and Survival Benefit Data Support Use of Anti-VEGF and TKI-Based Therapies
    • Rise in Clinical Trials and Pipeline Activity Creates Tailwinds for Innovation in First- and Second-Line Therapies
    • Integration of Real-World Evidence Enhances Reimbursement and Access for Novel Therapies in uHCC
    • Expanding Role of Interventional Oncology Drives Demand for TACE and Y-90 as Bridging or Adjunct Therapies
    • Liver Disease Co-Morbidities Highlight the Need for Tolerable and Liver-Sparing Therapeutic Approaches
    • Rising Healthcare Investment in Oncology Infrastructure Fuels Market Expansion for Systemic and Targeted uHCC Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Unresectable Hepatocellular Carcinoma Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Unresectable Hepatocellular Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy for Unresectable Hepatocellular Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy for Unresectable Hepatocellular Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chemotherapy for Unresectable Hepatocellular Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Molecularly Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Molecularly Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Molecularly Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cancer Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cancer Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Cancer Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Unresectable Hepatocellular Carcinoma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Unresectable Hepatocellular Carcinoma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Unresectable Hepatocellular Carcinoma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Unresectable Hepatocellular Carcinoma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Unresectable Hepatocellular Carcinoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Unresectable Hepatocellular Carcinoma by Treatment - Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Unresectable Hepatocellular Carcinoma by Treatment - Percentage Breakdown of Value Sales for Chemotherapy for Unresectable Hepatocellular Carcinoma, Molecularly Targeted Therapy, Immunotherapy and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Unresectable Hepatocellular Carcinoma by End-user - Hospitals End-User, Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Unresectable Hepatocellular Carcinoma by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION